Key Audit Findings
Vaccine makers have near-total legal immunity. The National Childhood Vaccine Injury Act of 1986 shielded manufacturers from most injury lawsuits. Injured parties must go through the VICP first — and can only sue in regular court if the fund denies their claim or they reject the award.
20–25% goes to attorneys and overhead, not claimants. HHS data shows legal fees, attorney costs, and administrative expenses have historically consumed roughly $1 in every $4–5 paid out — a ratio that has grown as contested SIRVA claims multiply.
The flu shot accounts for the plurality of all claims. Shoulder Injury Related to Vaccine Administration (SIRVA) — typically from an improperly administered injection — is now the single largest claim category, topping ~40% of all petitions. It has nothing to do with the vaccine itself.
The fund is financed by a hidden tax on your vaccines. A $0.75 excise tax per vaccine dose funds the program. You pay it every time you or your child receives a covered vaccine — it’s baked into the price and not disclosed at the point of care.
How It Works
How the VICP Works
Created by the National Childhood Vaccine Injury Act of 1986 and administered by HHS, the VICP is a no-fault federal compensation system. Injured parties file a petition in the U.S. Court of Federal Claims (“Vaccine Court”). A Special Master — not a jury — decides the case.
Claimants must first demonstrate the injury appears on the Vaccine Injury Table (a presumptive list) or prove causation. The government pays if the claim is accepted. Vaccine manufacturers pay nothing directly.
If you lose or reject the award, you may then sue the manufacturer in civil court — but the standards are extremely high and most suits fail.
Who Actually Pays
Every covered vaccine sold in the U.S. carries a $0.75 federal excise tax per dose, collected by the IRS and deposited into the Vaccine Injury Compensation Trust Fund.
As of 2025, the trust fund holds approximately $4.8 billion in reserves — though claims pace has accelerated. In FY 2023 alone, ~$500M was paid out, nearly double the pace of a decade ago.
Vaccine manufacturers contribute nothing to the fund directly. The cost is externalized to consumers through vaccine pricing and, indirectly, taxpayers via federal vaccine purchase programs.
SIRVA: The Dominant Claim Type
Shoulder Injury Related to Vaccine Administration (SIRVA) now represents roughly 40% of all VICP claims — and it has nothing to do with the vaccine’s chemical composition.
SIRVA occurs when a vaccine is injected too high on the arm, depositing the antigen into the subdeltoid bursa rather than muscle tissue, causing bursitis, rotator cuff tears, and chronic shoulder pain.
It is entirely preventable through proper technique. Yet claims exploded after 2017 when SIRVA was added to the Vaccine Injury Table, because patients could use the presumptive injury pathway without proving causation case-by-case.
The primary driver: flu shots administered at pharmacies, where staff may lack formal injection training.
The Attorney Fee Problem
Unlike most litigation, VICP pays petitioners’ attorney fees even on losing claims — provided the claim was filed in good faith with a reasonable basis. This is intentionally pro-claimant.
But it also creates incentives: fee applications have grown substantially, and attorneys receive fees regardless of outcome. In contested multi-year proceedings, legal fees per case can reach $50,000–$150,000 — on top of any award.
Historically 20–25% of total program payouts have gone to legal fees and administrative costs rather than injured claimants. In FY 2023, that implies $100–125M in non-claimant costs on ~$500M of total disbursements.
HHS does not publish a clean annual breakdown of fees vs. compensation — this figure is reconstructed from aggregated program reports.
Top Vaccines by Claims Filed (Program Cumulative)
Data from HHS HRSA VICP Data and Statistics report (updated quarterly). Figures reflect cumulative petitions filed since 1988 by vaccine type.
| Vaccine | Claims Filed | Compensated | % Compensated | Most Common Injury |
|---|---|---|---|---|
| Influenza (Flu) | ~9,500+ | ~4,400+ | ~46% | SIRVA (shoulder injury from improper injection) |
| Hepatitis B | ~1,500 | ~600 | ~40% | Demyelinating disorders (GBS, MS-like), SIRVA |
| DTaP / DTP / Td / Tdap | ~2,800 | ~1,100 | ~39% | Brachial neuritis, SIRVA, encephalopathy (DTP) |
| HPV (Gardasil) | ~900 | ~270 | ~30% | SIRVA, POTS/dysautonomia (contested), syncope |
| Tetanus (standalone) | ~500 | ~220 | ~44% | Brachial neuritis (Parsonage-Turner syndrome) |
| MMR / Measles / Mumps / Rubella | ~1,200 | ~400 | ~33% | Thrombocytopenic purpura (ITP), arthritis |
| Varicella (Chickenpox) | ~250 | ~80 | ~32% | Disseminated varicella, encephalitis |
| All Other / Multiple Vaccines | ~8,000+ | ~3,000+ | — | Incl. COVID-19 vaccine (CICP, not VICP), others |
Source: HHS HRSA — VICP Data and Statistics (quarterly). COVID-19 vaccines are covered under the separate Countermeasures Injury Compensation Program (CICP), not the VICP — payouts and standards differ significantly. Figures above are rounded and approximate; exact current figures at HRSA link.
Annual Payouts: 2015 – 2023
Approximate total compensation awarded per fiscal year. Post-2017 acceleration driven by SIRVA claims surge after flu was added to the Injury Table and pharmacy vaccinations expanded nationally.
2020 dip reflects COVID-related court slowdowns and deferred hearings; 2019 and 2023 peaks reflect SIRVA case resolution backlogs clearing. FY runs Oct 1–Sep 30. Figures approximate from HHS HRSA quarterly data reports.
What Injured Patients and Advocates Should Know
Filing a Claim
The VICP is the only venue for most vaccine injury claims. You must file a petition in the U.S. Court of Federal Claims within 3 years of symptom onset (or 2 years for a death claim). Missing this deadline forfeits your rights entirely.
You need a licensed attorney admitted to the Court of Federal Claims. The VICP maintains a list of attorneys. Attorney fees are paid by the program, not deducted from your award.
Statute of Limitations Trap
SIRVA has the same 3-year clock — but many patients don’t immediately connect their shoulder pain to a vaccine received months earlier. Delayed diagnosis of bursitis or a rotator cuff tear can eat into the filing window.
If you developed persistent shoulder pain within 48 hours of a vaccination (in the injected arm), document the onset date now and consult a VICP attorney immediately — don’t wait for a diagnosis.
The COVID-19 Exception
COVID-19 vaccines are NOT covered by the VICP. They fall under the Countermeasures Injury Compensation Program (CICP), which has a 1-year filing deadline, does not pay attorney fees, and has far lower compensation rates.
As of 2024, CICP has compensated a small fraction of COVID vaccine injury petitions. Patient advocates are pushing to move COVID vaccines into VICP coverage.
FOIA & Public Data
HRSA publishes quarterly VICP data tables (claims filed, compensated, dismissed, and compensation paid by vaccine type) at hrsa.gov/vaccine-compensation/data.
Decisions by Special Masters are public record and searchable via the Court of Federal Claims PACER system. Annual trust fund financial statements are filed with the U.S. Treasury.
Primary Sources:
HHS HRSA — VICP Data and Statistics (quarterly) · HRSA VICP Program Overview · VICP Statistics Report (PDF, latest)
42 U.S.C. § 300aa-10 et seq. — National Vaccine Injury Act text
Annual payout figures are approximated from HHS quarterly data reports and program trust fund statements. Exact current figures available at the HRSA VICP data page above. Claim counts by vaccine type reflect cumulative program-life totals. COVID-19 vaccine injury claims fall under CICP, not VICP, and are excluded from statistics above.
This page is for informational and accountability purposes only and does not constitute legal or medical advice. AccountableHub has no affiliation with HHS, HRSA, or the U.S. Department of Justice.